Expertise in
21
conditions

Dr. Jonathan C. Huang

Gastroenterology
University Of Rochester
601 Elmwood Ave, 
Rochester, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
21
conditions
University Of Rochester
601 Elmwood Ave, 
Rochester, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jonathan Huang is a Gastroenterologist in Rochester, New York. Dr. Huang is highly rated in 21 conditions, according to our data. His top areas of expertise are Cirrhosis, Primary Biliary Cholangitis, Hepatitis, Endoscopy, and Colonoscopy.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gastroenterology
Licenses
Internal Medicine in IL
Hospital Affiliations
Nicholas H Noyes Memorial Hospital
Strong Memorial Hospital
F F Thompson Hospital
Highland Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

UNIVERSITY OF ROCHESTER
601 Elmwood Ave, Rochester, NY 14642
Other Locations
HIGHLAND HOSPITAL OF ROCHESTER
1000 S Ave, Rochester, NY 14620

Additional Areas of Focus

Dr. Huang has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
Enrollment Status: Recruiting
Publish Date: June 06, 2025
Intervention Type: Drug
Study Drug: Volixibat
Study Phase: Phase 2
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Lonafarnib, Ritonavir, PEG IFN-alfa-2a
Study Phase: Phase 3
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
Enrollment Status: Terminated
Publish Date: March 09, 2023
Intervention Type: Drug
Study Drug: Obeticholic Acid 
Study Phase: Phase 4
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: August 02, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy & Safety of Oral GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and With Persistently Elevated Alkaline Phosphatase
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy & Safety of Oral GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and With Persistently Elevated Alkaline Phosphatase
Enrollment Status: Completed
Publish Date: June 29, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Terminated
Publish Date: November 25, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

2 Total Publications

Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B Study.
Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B Study.
Journal: Clinical and translational gastroenterology
Published: June 12, 2024
Similar Doctors
Expertise in
23
conditions
Dr. Truptesh H. Kothari
Gastroenterology
Expertise in
23
conditions
Dr. Truptesh H. Kothari
Gastroenterology

University Of Rochester

601 Elmwood Ave, 
Rochester, NY 
 (0.1 mi)
585-275-2100
Languages Spoken:
English

Truptesh Kothari is a Gastroenterologist in Rochester, New York. Dr. Kothari is highly rated in 23 conditions, according to our data. His top areas of expertise are Hereditary Pancreatitis, Acute Pancreatitis, Chronic Pancreatitis, Endoscopy, and Gastric Bypass.

Expertise in
40
conditions
Dr. Asad Ullah
Gastroenterology
Expertise in
40
conditions
Dr. Asad Ullah
Gastroenterology

Highland Hospital Of Rochester

1000 S Ave, 
Rochester, NY 
 (1.3 mi)
585-473-2200
Languages Spoken:
English

Asad Ullah is a Gastroenterologist in Rochester, New York. Dr. Ullah is highly rated in 40 conditions, according to our data. His top areas of expertise are Chronic Pancreatitis, Childhood Pancreatitis, Bile Duct Stricture, Endoscopy, and Gastrectomy.

Expertise in
12
conditions
Dr. Nanda Kerkar
Pediatric Gastroenterology | Transplant Surgery | Pediatrics
Expertise in
12
conditions
Dr. Nanda Kerkar
Pediatric Gastroenterology | Transplant Surgery | Pediatrics
601 Elmwood Ave, 
Rochester, NY 
 (0.1 mi)
585-275-2647
Languages Spoken:
English

Nanda Kerkar is a Pediatric Gastroenterologist and a Transplant Surgeon in Rochester, New York. Dr. Kerkar is highly rated in 12 conditions, according to our data. Her top areas of expertise are Autoimmune Hepatitis, Biliary Atresia, Alagille Syndrome, Liver Transplant, and Pancreas Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Huang's expertise for a condition
ConditionClose
    View All 17 Advanced Conditions
    View All 25 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile